- Revenue and EPS Growth: McKesson reported $106.2 billion in revenue (11% increase) and $9.34 earnings per diluted share (16% increase), driven by oncology, biopharma, and distribution segments.
- Oncology & Multispecialty Performance: Segment revenue surged 37% to $X billion, with operating profit up 57%, fueled by Prism Vision and Core Ventures acquisitions.
- 2026 Earnings Guidance Raised: Adjusted EPS guidance set at $38.80–$39.20 (17–19% growth), with revenue growth projected at 12–16% and operating profit growth at 13–17%.
- North American Pharma Momentum: Segment revenue increased 9%, with 6% operating profit growth, supported by specialty distribution and inventory efficiency gains.
- Balance Sheet Strength: $3 billion in cash and $4.4–4.8 billion in free cash flow, supporting $2 billion in share repurchases and $101 million in dividends.
Segment Performance
The North American Pharmaceutical segment saw revenue increase by 9% and operating profit increase by 6%. The Oncology and Multispecialty segment reported revenue growth of 37% and operating profit growth of 57%, driven by strong underlying performance and the company's connectivity and workflow integration. The Prescription Technology Solutions segment saw strong operating profit results, driven by the addition of 50 new programs across 43 unique brands and improved efficiency.
Outlook and Guidance
McKesson Corporation raised and narrowed its fiscal 2026 earnings per diluted share guidance range to $38.80 to $39.20, representing 17 to 19% growth over the prior year. The company expects revenue growth of 12 to 16% and operating profit growth of 13% to 17%. The oncology and multispecialty segment is expected to grow 29-33% in revenue and 51-55% in operating profit.
Valuation and Metrics
With a P/E Ratio of 25.27 and an EV/EBITDA of 18.35, McKesson Corporation's valuation appears reasonable given its strong growth prospects. The company's ROIC of 21.67% indicates efficient use of capital. Analysts estimate next year's revenue growth at 8.4%, which is slightly lower than the current year's growth rate. The company's dividend yield of 0.37% and free cash flow yield of 6.25% provide a reasonable return to shareholders.
Regulatory Environment
McKesson Corporation is navigating the evolving policy landscape, including the impact of IRA and NFP, and is focused on influencing factors outside of its direct negotiation. The company believes its distributor value proposition is strong and is well-positioned to adapt to the changing regulatory environment.